Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models - Fujimori, Y; Katsuno, K; Nakashima, I; Ishikawa-Takemura, Y; Fujikura, H; Isaji, M (J Pharmacol Exp Ther, 2008)